# Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

> **NCT02379390** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 8 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Cabazitaxel XRP6258
- **DRUG:** Ezalutamide
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02379390
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-17
- **Primary completion:** 2018-05-10
- **Final completion:** 2018-05-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Unsatisfactory patient accrual
- **Last updated:** 2019-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379390, "Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02379390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*